These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 9613782

  • 1. Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood.
    Gruhn B, Häfer R, Kosmehl H, Fuchs D, Zintl F.
    Bone Marrow Transplant; 1998 May; 21(9):901-7. PubMed ID: 9613782
    [Abstract] [Full Text] [Related]

  • 2. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 3. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells.
    Miura Y, Ueda M, Takami A, Shiobara S, Nakao S, Hess AD.
    Bone Marrow Transplant; 2003 Oct; 32(8):785-90. PubMed ID: 14520422
    [Abstract] [Full Text] [Related]

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 6. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G, Beguin Y.
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [Abstract] [Full Text] [Related]

  • 7. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R, Enczmann J, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Wernet P, Göbel U, Laws HJ, Dilloo D.
    Klin Padiatr; 2005 Dec; 217(3):135-41. PubMed ID: 15858704
    [Abstract] [Full Text] [Related]

  • 8. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y, Thoburn CJ, Bright EC, Hess AD.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [Abstract] [Full Text] [Related]

  • 9. Graft versus host disease in autologous stem cell transplantation.
    Marin GH, Porto A, Prates V, Napal J, Etchegogen O, Rubens L, Bordone J, Castelletto R, Buschiazzo H, Morales V, Milone J.
    J Exp Clin Cancer Res; 1999 Jun; 18(2):201-8. PubMed ID: 10464707
    [Abstract] [Full Text] [Related]

  • 10. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont M, Estrada-García I, Montiel-Cervantes L, Tripp-Villanueva F, Ayala-Sánchez M, García-León LD, Borbolla-Escoboza JR, Mayani H.
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.
    Talbot DC, Powles RL, Sloane JP, Rose J, Treleaven J, Aboud H, Helenglass G, Parikh P, Smith C, Rowley M.
    Bone Marrow Transplant; 1990 Jul; 6(1):17-20. PubMed ID: 2202461
    [Abstract] [Full Text] [Related]

  • 12. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
    Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R, Miller C, Marcellus D, Abrams R, Hess A.
    Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.
    Transplantation; 2009 Dec 15; 88(11):1312-8. PubMed ID: 19996931
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
    Stein M, Feldman E, Seiter K, Chiao JW, Goff H, Baskind P, Beer M, Ahmed T.
    Bone Marrow Transplant; 1999 Nov 15; 24(10):1073-7. PubMed ID: 10578157
    [Abstract] [Full Text] [Related]

  • 15. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
    Kline J, Subbiah S, Lazarus HM, van Besien K.
    Bone Marrow Transplant; 2008 Mar 15; 41(6):505-13. PubMed ID: 18026144
    [Abstract] [Full Text] [Related]

  • 16. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
    Liem LM, van Noort JT, Goulmy E.
    Bone Marrow Transplant; 1996 Jul 15; 18(1):73-8. PubMed ID: 8831998
    [Abstract] [Full Text] [Related]

  • 17. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J, Casaño J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F, Gomez P, Serrano J, Herrera C, Torres A.
    Br J Haematol; 2004 Sep 15; 126(5):697-703. PubMed ID: 15327522
    [Abstract] [Full Text] [Related]

  • 18. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
    Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL.
    Biol Blood Marrow Transplant; 2006 Jan 15; 12(1 Suppl 2):22-30. PubMed ID: 16399598
    [Abstract] [Full Text] [Related]

  • 19. Progressive autologous graft-versus-host disease induced by cyclosporin A.
    Barredo JC, Yusuf U, Hahn A, Abboud MR, Laver J.
    Bone Marrow Transplant; 1996 Sep 15; 18(3):659-62. PubMed ID: 8879637
    [Abstract] [Full Text] [Related]

  • 20. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease.
    Faaij CM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M, Révész T, Egeler RM, van Tol MJ, Annels NE.
    Br J Haematol; 2006 Jun 15; 133(5):538-49. PubMed ID: 16681643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.